Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

121. Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer

Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer SGO member update: Emerging data on the surgical approach for radical hysterectomy in the treatment of women with cervical cancer | SGO Secondary menu Working to Eradicate Gynecologic Cancers Main menu Search | | Are you sure you wish to delete this record?

2019 Society of Gynecologic Oncology

122. Osimertinib (Tagrisso) - non-small cell lung cancer (NSCLC)

Osimertinib (Tagrisso) - non-small cell lung cancer (NSCLC) 1 Published 9 September 2019 1 SMC2171 osimertinib 40mg and 80mg film-coated tablet (Tagrisso®) AstraZeneca Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the end of life and orphan (...) equivalent process osimertinib (Tagrisso ® ) is not recommended for use within NHSScotland. Indication under review: as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. Osimertinib, compared with two other EGFR tyrosine kinase inhibitors, improved progression-free survival in adults with locally advanced or metastatic NSCLC with activating EGFR mutations

2019 Scottish Medicines Consortium

123. Breast Cancer: Medication Use to Reduce Risk

Breast Cancer: Medication Use to Reduce Risk Final Recommendation Statement: Breast Cancer: Medication Use to Reduce Risk - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Breast Cancer: Medication Use to Reduce Risk Recommendations made by the USPSTF are independent of the U.S. government. They should (...) not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Women at increased risk for breast cancer The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects. Women not at increased risk

2019 U.S. Preventive Services Task Force

124. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension

Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension It remains unclear whether patients with positive surgical margins or extracapsular extension benefit from adjuvant radiotherapy following radical prostatectomy.To compare the effectiveness and tolerability of adjuvant radiotherapy following radical prostatectomy.This was a randomised, open-label, parallel-group (...) trial. A total of 250 patients were enrolled between April 2004 and October 2012 in eight Finnish hospitals, with pT2 with positive margins or pT3a, pN0, M0 cancer without seminal vesicle invasion.A total of 126 patients received adjuvant radiotherapy at 66.6Gy.The primary endpoint was biochemical recurrence-free survival, which we analysed using the Kaplan-Meier method and Cox proportional hazard regression. Overall survival, cancer-specific survival, local recurrence, and adverse events were

2019 EvidenceUpdates

125. Neoadjuvant Therapy Vs Upfront Surgery for Clinical T2N0 Esophageal Cancer: A Systematic Review

Neoadjuvant Therapy Vs Upfront Surgery for Clinical T2N0 Esophageal Cancer: A Systematic Review The optimal approach to clinical T2N0 (cT2N0) esophageal cancer is unclear. Our objective is to perform a systematic review investigating whether neoadjuvant therapy results in better outcomes compared with upfront surgery in cT2N0 esophageal cancer.We performed a systematic review and meta-analysis of randomized and nonrandomized studies (1995 to 2017) comparing use of neoadjuvant therapy (...) with upfront surgery in the treatment of cT2N0 esophageal cancer. Independent and duplicate assessment was used. All meta-analytical techniques were performed in RevMan 5.3.Nine cohort studies, including 5433 patients, were included for meta-analysis. Use of neoadjuvant therapy was associated with significantly higher complete resection rates compared with upfront surgery (risk ratio, 0.67; 95% confidence interval, 0.55 to 0.81; P < .001). There was no difference in 5-year overall or recurrence-free

2019 EvidenceUpdates

126. Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial

Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial Hybrid minimally invasive esophagectomy (HMIE) has been shown to reduce major postoperative complications compared with open esophagectomy (OE) for esophageal cancer.The aim of this study was to compare short- and long-term health-related quality of life (HRQOL) following (...) HMIE and OE within a randomized controlled trial.We performed a multicenter, open-label, randomized controlled trial at 13 study centers between 2009 and 2012. Patients aged 18 to 75 years with resectable cancers of the middle or lower third of the esophagus were randomized to undergo either transthoracic OE or HMIE. Patients were followed-up every 6 months for 3 years postoperatively and global health assessed with EORTC-QLQC30 and esophageal symptoms assessed with EORTC-OES18.The short-term

2019 EvidenceUpdates

127. Pembrolizumab (Keytruda) - non-small cell lung cancer (NSCLC) in adults.

Pembrolizumab (Keytruda) - non-small cell lung cancer (NSCLC) in adults. 1 Published 9 September 2019 1 SMC2187 pembrolizumab 25mg/mL concentrate for solution for infusion and 50mg powder for concentrate for solution for infusion (Keytruda®) Merck Sharp & Dohme UK Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission assessed under the end of life medicine process pembrolizumab (Keytruda ® ) is accepted for restricted use within NHSScotland. Indication under review: In combination with carboplatin and either paclitaxel or nab- paclitaxel, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults. SMC restriction: in combination with carboplatin and paclitaxel in patients whose tumours express programmed death ligand 1 (PD-L1

2019 Scottish Medicines Consortium

128. Frequently Asked Questions on Position Statement – Testing for Ovarian Cancer in Asymptomatic Women

Frequently Asked Questions on Position Statement – Testing for Ovarian Cancer in Asymptomatic Women canceraustralia.gov.au About Ovarian Cancer What is ovarian cancer? Ovarian cancer is cancer that affects a woman’s reproductive organs. It occurs when abnormal cells in the ovaries, fallopian tubes or peritoneum (the cells lining the abdomen) grow in an uncontrolled way. What affects a woman’s risk of developing ovarian cancer? Several things – called risk factors – can affect a woman’s risk (...) of developing ovarian cancer. Having one or more of these risk factors does not mean that a woman will develop ovarian cancer. Similarly, having no risk factors does not mean that a woman will not develop ovarian cancer. The most significant risk factors for ovarian cancer are getting older and having a family history of breast or ovarian cancer. Having a family history means having one or more blood relatives (such as a mother, sister or daughter) who has had breast or ovarian cancer. In some women

2019 Cancer Australia

129. Risk Factors for Endometrial Cancer - A review of the evidence

Risk Factors for Endometrial Cancer - A review of the evidence Risk factors for endometrial cancer: A review of the evidence 2019 Endometrial cancer risk factors: A review of the evidence i Risk factors for endometrial cancer: A review of the evidence was prepared and produced by: Cancer Australia Locked Bag 3 Strawberry Hills NSW 2012 Australia Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 canceraustralia.gov.au © Cancer Australia 2019. ISBN Online: 978–1–74127–342–7 Recommended citation Cancer (...) Australia, 2019. Risk factors for endometrial cancer: A review of the evidence, Cancer Australia, Surry Hills, NSW. Risk factors for endometrial cancer: A review of the evidence can be downloaded from the Cancer Australia website: canceraustralia.gov.au Copyright statements Internet sites This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your

2019 Cancer Australia

130. Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy

Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy Axillary radiotherapy - Health Technology Wales > Axillary radiotherapy Axillary radiotherapy Topic Status Complete Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy. Summary This report (...) was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER030 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services

2019 Health Technology Wales

131. Daily online image-guided radiotherapy with reduced treatment margins for people with anal cancer

Daily online image-guided radiotherapy with reduced treatment margins for people with anal cancer Daily online image-guided radiotherapy (anal cancer) - Health Technology Wales > Daily online image-guided radiotherapy (anal cancer) Daily online image-guided radiotherapy (anal cancer) Topic Status Complete Daily online image-guided radiotherapy with reduced treatment margins for people with anal cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale (...) University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER035 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend

2019 Health Technology Wales

132. Daily online image-guided radiotherapy for people undergoing radical bladder cancer treatment

Daily online image-guided radiotherapy for people undergoing radical bladder cancer treatment Daily online image-guided radiotherapy (bladder cancer) - Health Technology Wales > Daily online image-guided radiotherapy (bladder cancer) Daily online image-guided radiotherapy (bladder cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical bladder cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale (...) University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER037 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend

2019 Health Technology Wales

133. Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment

Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment Daily online image-guided radiotherapy (lung cancer) - Health Technology Wales > Daily online image-guided radiotherapy (lung cancer) Daily online image-guided radiotherapy (lung cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical lung cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health (...) Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER036 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full

2019 Health Technology Wales

134. Internal mammary node irradiation for people with high-risk early breast cancer

Internal mammary node irradiation for people with high-risk early breast cancer Internal mammary node irradiation - Health Technology Wales > Internal mammary node irradiation Internal mammary node irradiation Topic Status Complete Internal mammary node irradiation for people with high-risk early breast cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence (...) on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER031 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact

2019 Health Technology Wales

135. Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment

Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment Daily online image-guided radiotherapy (prostate cancer) - Health Technology Wales > Daily online image-guided radiotherapy (prostate cancer) Daily online image-guided radiotherapy (prostate cancer) Topic Status Complete Daily online image-guided radiotherapy for people undergoing radical prostate cancer treatment. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale (...) University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER038 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend

2019 Health Technology Wales

136. Partial breast irradiation for people with early breast cancer

Partial breast irradiation for people with early breast cancer Partial breast irradiation - Health Technology Wales > Partial breast irradiation Partial breast irradiation Topic Status Complete Partial breast irradiation for people with early breast cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation (...) discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER029 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking at this document because We may like to contact you by email to find out more about how you used

2019 Health Technology Wales

137. Passive respiratory gating with stereotactic ablative body radiotherapy for people with liver cancer

Passive respiratory gating with stereotactic ablative body radiotherapy for people with liver cancer Passive respiratory gating with stereotactic ablative body radiotherapy - Health Technology Wales > Passive respiratory gating with stereotactic ablative body radiotherapy Passive respiratory gating with stereotactic ablative body radiotherapy Topic Status Complete Passive respiratory gating with stereotactic ablative body radiotherapy for people with liver cancer. Summary This report (...) was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre. It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER040 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services

2019 Health Technology Wales

138. Volumetric modulated arc radiotherapy for people with lung cancer

Volumetric modulated arc radiotherapy for people with lung cancer Volumetric modulated arc radiotherapy (lung cancer) - Health Technology Wales > Volumetric modulated arc radiotherapy (lung cancer) Volumetric modulated arc radiotherapy (lung cancer) Topic Status Complete Volumetric modulated arc radiotherapy for people with lung cancer. Summary This report was prepared by Health Technology Wales and Cedar (Cardiff & Vale University Health Board) on behalf of Velindre Cancer Centre (...) . It summarises the existing evidence on the technology of interest to support a prioritisation discussion related to the implementation of radiotherapy procedures/techniques at Velindre Cancer Centre. Topic Exploration Report TER034 (03.2019) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it. Full Name Job Title Organisation Email I'm looking

2019 Health Technology Wales

139. Diagnosis and staging of patients with ovarian cancer

Diagnosis and staging of patients with ovarian cancer National Patient Safety Office Oifig Náisiúnta um Shábháilteacht Othar Diagnosis and staging of patients with ovarian cancer National Clinical Guideline No. 20 August 2019This National Clinical Guideline has been developed by the National Cancer Control Programme (NCCP) Guideline Development Group, within the Health Services Executive (HSE). Using this National Clinical Guideline This National Clinical Guideline applies to adults (over 18 (...) years old) that have a suspected diagnosis of ovarian cancer and adults with newly diagnosed ovarian cancer or recurrent ovarian cancer. This guideline is intended for all health professionals involved in the diagnosis and staging of patients with ovarian cancer and health professionals working in Genetics Services. While the Chief Executive Officer (CEO), General Manager and the Clinical Director of the hospital have corporate responsibility for the implementation of the recommendations

2019 National Clinical Guidelines (Ireland)

140. Darolutamide (Nubeqa) - adult patients with non-metastatic castration resistant prostate cancer

Darolutamide (Nubeqa) - adult patients with non-metastatic castration resistant prostate cancer Drug Approval Package: NUBEQA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: NUBEQA Company: Bayer HealthCare Pharmaceuticals Inc. Application Number: 212099 Approval Date: 07/30/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2019 FDA - Drug Approval Package